PRESS-RELEASE ·Filed May 11, 2026
Press release · Announcement
Actionable Insight • Neutral
The webinar may provide clinical data updates, but with no preliminary results disclosed, the immediate impact is negligible. Monitor for any material data or regulatory catalysts from the trial.
Final — all horizons settled through T+60d
CMND ▼ -66.17% at T+60d
NEUTRAL call -66.17% · α vs SPY -70.56% · entry $5.20 → $1.76
T+1d
+3.81%
call +3.81% · α +3.94%
$5.40
settled 6mo ago
T+5d
-26.93%
call -26.93% · α -26.85%
$3.80
settled 5mo ago
T+20d
-34.83%
call -34.83% · α -34.53%
$3.39
settled 5mo ago
T+60d
-66.17%
call -66.17% · α -70.56%
$1.76
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Clearmind Medicine announced a live webinar on June 10, 2026, to discuss early clinical data from its Phase I/IIa trial of CMND-100 (MEAI) for Alcohol Use Disorder. No new data or financial results were disclosed in the press release.
Key Facts
- Webinar scheduled for June 10, 2026, featuring clinical investigators from Yale and Johns Hopkins.
- CMND-100 is a non-hallucinogenic MEAI-based drug candidate for Alcohol Use Disorder.
- No safety or efficacy data was released in the press release.
Financial Impact
No financial impact from this announcement
Risk Factors
- Clinical trial failure or negative results could severely impact the stock.
- Low liquidity and micro-cap volatility pose trading risks.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291795 |
63 reports for CMND
53% Hit rate @ T+60 Went positive at some point 16 of 21 best @ T+60▲ +75.73%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
Showing 10 of 63
US Market Status
Market Closed — Opens in 5h 38m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers